Comparison of effects of aliskiren-based combination therapy between CCB and ARB in hypertensive patients with chronic kidney disease

Comparison of effects of aliskiren-based combination therapy between CCB and ARB in hypertensive patients with chronic kidney disease - Comparison of effects of aliskiren-based combination therapy between CCB and ARB in hypertensive patients with chronic kidney disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006821

Enrollment

100

Registered

2011-12-02

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, chronic kidney disease

Interventions

CCB group: In the intervention phase, add-on combination therapy will be performed by amlodipine 2.5-10 mg daily for 24 weeks. ARB group: In the intervention phase, add-on combination therapy will b

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Chronic kidney disease.3) 2) On monotherapy by aliskiren 150 mg daily. 3) Clinic SBP >= 130 mmHg or clinic DBP>=80 mmHg.

Exclusion criteria

Exclusion criteria: 1) CKD stage 5 or on dialysis therapy 2) History of hypersensitivity to aliskiren, amlodipine, or valsartan. 3) Pregnant or suspicious women. 4) Treatment with itraconazole, cyclosporine. 5) Judged as inappropriate for the study

Design outcomes

Primary

Measure	Time frame
1.Body weight, BMI, abdominal circumference. 2.Clinic BP 3.Home BP 4.Ambulatory BP 5.Renal function (eGFR), urinary protein and albumin excretion, urinary sodium excretion. Urinary type IV collagen and angiotensinogen. 6.Vascular function. Central BP, ABI/PWV, FMD. 7.Glucose metabolism markers. 8.Lipid metabolism markers. 9.Endocrine system. PRA, PAC, BNP. 10.Inflammatory and oxidative stress markers.	—

Measure

Time frame

1.Body weight, BMI, abdominal circumference. 2.Clinic BP 3.Home BP 4.Ambulatory BP 5.Renal function (eGFR), urinary protein and albumin excretion, urinary sodium excretion. Urinary type IV collagen and angiotensinogen. 6.Vascular function. Central BP, ABI/PWV, FMD. 7.Glucose metabolism markers. 8.Lipid metabolism markers. 9.Endocrine system. PRA, PAC, BNP. 10.Inflammatory and oxidative stress markers.

—

Countries

Japan

Contacts

Public ContactKouichi Tamura

Yokohama City University Graduate School of Medicine Department of Medical Science and Cardiorenal Medicine

tamukou@med.yokohama-cu.ac.jp045-787-26358

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026